medical stocks

presented by
Devices & Diagnostics

BSX scores FDA device approval for drug-eluting stent for coronary artery disease patients

Boston Scientific (BSX) received FDA device approval for its Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, a next-gen polymer drug-eluting stent. The product launches immediately in the U.S. It will be used to treat patients with coronary artery disease. The company boasts the system offers “unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, […]

presented by
Devices & Diagnostics

Boston Scientific gets FDA clearance and CE Mark for embolization catheter

Boston Scientific (BSX) received FDA clearance and the CE Mark for its Direxion Torqueable Microcatheter. The catheter is the company’s newest addition to its peripheral embolization medical device technology portfolio. Radiologists use peripheral embolization to treat liver cancer and uterine fibroids, among other conditions. “It involves deliberately blocking a blood vessel to prevent blood flow to […]

presented by
Devices & Diagnostics

BSX receives CE Mark for deep brain stimulation system as dystonia treatment

Boston Scientific (BSX) announced it has received the CE Mark for its Vercise Deep Brain Stimulation System for the treatment of dystonia, “a neurological movement disorder characterized by involuntary muscle contractions.” Dystonia is the third most common movement disorder after Parkinson’s disease and essential tremor, and more than 500,000 patients in Europe have it, according […]